---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-244201"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:04:00.225055+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Intellia Phase 2 NTLA-2002: 8/11 patients attack-free after single dose; 77% attack reduction vs placebo

## Summary
- Mean monthly attack rate reduced by 77% (50 mg) vs placebo during weeks 1-16; 81% during weeks 5-16.
- Eight of 11 patients in 50 mg arm had zero attacks over 16 weeks and remained attack-free through median 8-month follow-up.
- Kallikrein protein reduction: 86% mean reduction from baseline at week 16 (50 mg) vs 55% (25 mg).
- Well-tolerated; no serious AEs in NTLA-2002 arms; most common AEs were headache, fatigue, nasopharyngitis.
- 50 mg dose selected for global Phase 3 HAELO study, which is actively screening patients.

## SEC filing metadata
- accession: 0001193125-24-244201
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312524244201/0001193125-24-244201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312524244201/d842130d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-244201
- JSON: https://secwatch.observer/filing/0001193125-24-244201.json
- Plain text: https://secwatch.observer/filing/0001193125-24-244201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.